東北大学加齢医学研究所 臨床腫瘍学分野 東北大学 腫瘍内科

研究関係

HOME < 研究業績 < 英文論文 2017年度

英文論文 2017年度

  1. Miguchi, M.,Hinoi, T.,Tanakaya, K.,Yamaguchi, T.,Furukawa, Y.,Yoshida, T.,Tamura, K.,Sugano, K.,Ishioka, C.,Matsubara, N.,Tomita, N.,Arai, M.,Ishikawa, H.,Hirata, K.,Saida, Y.,Ishida, H.,Sugihara, K.: Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Surg Today 48. 810-814. Mar 24(2018)
  2. Yamaguchi, S.,Takahashi, S.,Mogushi, K.,Izumi, Y.,Nozaki, Y.,Nomizu, T.,Kakugawa, Y.,Ishida, T.,Ohuchi, N.,Ishioka, C.,Kato, S.: Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. Oncotarget 9. 14193-14206. Mar 6(2018)
  3. Yamada, Y.,Denda, T.,Gamoh, M.,Iwanaga, I.,Yuki, S.,Shimodaira, H.,Nakamura, M.,Yamaguchi, T.,Ohori, H.,Kobayashi, K.,Tsuda, M.,Kobayashi, Y.,Miyamoto, Y.,Kotake, M.,Shimada, K.,Sato, A.,Morita, S.,Takahashi, S.,Komatsu, Y.,Ishioka, C.: S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29. 624-631. Mar 1(2018)
  4. Bando, H.,Shimodaira, H.,Fujitani, K.,Takashima, A.,Yamaguchi, K.,Nakayama, N.,Takahashi, T.,Oki, E.,Azuma, M.,Nishina, T.,Hironaka, S.,Komatsu, Y.,Shitara, K.: A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 91. 86-91. Mar(2018)
  5. Horie, S.,Oya, M.,Nangaku, M.,Yasuda, Y.,Komatsu, Y.,Yanagita, M.,Kitagawa, Y.,Kuwano, H.,Nishiyama, H.,Ishioka, C.,Takaishi, H.,Shimodaira, H.,Mogi, A.,Ando, Y.,Matsumoto, K.,Kadowaki, D.,Muto, S.: Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 22. 210-244. Feb(2018)
  6. Takahashi, H.,Takahashi, M.,Ohnuma, S.,Unno, M.,Yoshino, Y.,Ouchi, K.,Takahashi, S.,Yamada, Y.,Shimodaira, H.,Ishioka, C.: microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. BMC Cancer 17. 723-737. Nov 07(2017)
  7. Ito, S. E.,Shirota, H.,Kasahara, Y.,Saijo, K.,Ishioka, C.: IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol Immunother 66. 1485-1496. Nov(2017)
  8. Saijo, K.,Imai, H.,Chikamatsu, S.,Narita, K.,Katoh, T.,Ishioka, C.: Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor. Cancer Sci 108. 1469-1475. Jul(2017)
  9. Okada, Y.,Kato, S.,Sakamoto, Y.,Oishi, T.,Ishioka, C.: Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines. Oncol Rep 38. 31-42. Jul(2017)
  10. Hiraide, S.,Ono, S.,Kato, S.: Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma). Case Rep Oncol 10. 420-427. May-Aug(2017)
  11. Takahashi, M.,Takahashi, M.,Komine, K.,Yamada, H.,Kasahara, Y.,Chikamatsu, S.,Okita, A.,Ito, S.,Ouchi, K.,Okada, Y.,Imai, H.,Saijo, K.,Shirota, H.,Takahashi, S.,Mori, T.,Shimodaira, H.,Ishioka, C.: The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study. PLoS One 12. e0179694. Jun 24(2017)
  12. Takahashi, M.,Komine, K.,Imai, H.,Okada, Y.,Saijo, K.,Takahashi, M.,Shirota, H.,Ohori, H.,Takahashi, S.,Chiba, N.,Mori, T.,Shimodaira, H.,Ishioka, C.: Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. PLoS One 12. e0176972. May 11(2017)
  13. Shitara, K.,Takashima, A.,Fujitani, K.,Koeda, K.,Hara, H.,Nakayama, N.,Hironaka, S.,Nishikawa, K.,Makari, Y.,Amagai, K.,Ueda, S.,Yoshida, K.,Shimodaira, H.,Nishina, T.,Tsuda, M.,Kurokawa, Y.,Tamura, T.,Sasaki, Y.,Morita, S.,Koizumi, W.: Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2. 277-287. Apr(2017)

ページの先頭へ戻る

© 2006 Department of Medical Oncology, Tohoku University Hospital All rights reserved.